

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



JOINN LABORATORIES (CHINA) CO., LTD.

北京昭衍新藥研究中心股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 6127)

SUPPLEMENTAL ANNOUNCEMENT

(Company, Group) 27 A, 2023
 Announcement, ()
 B, A
 65% B, 35% * (北京七溪亦昭投資有限公司) (Beijing Qixi), 35% * (太倉香塘吳華置業有限公司) (Taicang Xiangtang).
 B, C
 (B), 47.6%, 37.4%, 5%, 5% (張洪山), 5% (李濤).
 55.25% B,
 C
 (蘇州香塘吳華科技發展有限公司) 52%, (香塘集團有限公司) 48%, C (太倉市城市建設投資集團有限公司), 55% (顧建平), 45% (顧振其).
 C, A, A
 (太倉市政府國有資產監督管理辦公室).

* For identification purpose only

B 股, 红 筹 B 股,
JOINN Laboratories (China) Co., Ltd.
Feng Yuxia
Chairperson

B 股, 红 筹 B 股, C
3 月 2023

As at the date of this announcement, the Board comprises Ms. Feng Yuxia as the Chairperson and executive Director, Mr. Zuo Conglin, Mr. Gao Dapeng, Ms. Sun Yunxia and Dr. Yao Dalin as executive Directors, and Mr. Sun Mingcheng, Dr. Zhai Yonggong, Mr. Ou Xiaojie and Mr. Zhang Fan as independent non-executive Directors.